Dr. D. Beard, Author At PanNASH

NASH Observatory Commented Articles Definitions Articles

Imaging biomarkers of NAFLD, NASH, and fibrosis

Globally, liver biopsy remains the reference standard for staging NAFLD severity. To diagnose NAFLD and quantify liver fat, MRI proton density fat fraction may be more informative than liver biopsy. In this review, V. Ajmera and R. Loomba (University of California, USA) critically examine the use...

July 29, 2021

NASH Observatory Commented Articles Diagnosis Articles

NAFLD: no liver biopsy in 2/3 patients of a real-world cohort

Much of the current data on NAFLD are derived from biopsy-based studies that may introduce ascertainment and selection bias. Selection of patients for liver biopsy has implications for clinical practice and the reported epidemiology of NAFLD. The aim of this study was to determine patient factors predictive....

July 26, 2021

NASH Observatory Commented Articles Pathophysiology Articles

Alterations in gut microbiota in NASH

NAFLD pathophysiology has been linked to lower microbial diversity and a weakened intestinal barrier, exposing the host to bacterial components and stimulating pathways of immune defence and inflammation via toll-like receptor signaling. Moreover, this activation of inflammation in hepatocytes induces progression from simple steatosis to NASH...

July 21, 2021

NASH Observatory Commented Articles Comorbidities Articles Diagnosis Articles

NAFLD in patients with schizophrenia: early detection should be conducted

ndividuals with schizophrenia have high levels of medical comorbidity and cardiovascular risk factors. Patients with schizophrenia should receive regular monitoring and adequate treatment of cardio-metabolic risk factors. Nevertheless, little is known regarding NAFLD in patients with schizophrenia. A. Koreki et al. analysed the medical...

July 14, 2021

NASH Observatory Commented Articles Epidemiology Articles

NAFLD burden in Asia and MENA regions

P. Golabi et al. assessed the burden of liver complications (cirrhosis and liver cancer) related to NAFLD between 2009-2019 in Asia and MENA (Middle East and Northern Africa) regions, using Global Burden of Disease data to assess incidence, mortality, and disability-adjusted-life-years (DALYs)...

July 12, 2021

NASH Observatory Commented Articles Epidemiology Articles

Obesity and liver cancer in Japan

It is estimated that there are more than 10 million NAFLD patients in Japan. 10-20% of NASH patients will progress to liver cirrhosis and 2-3% of them will develop hepatocellular carcinoma per year. In their review, H. Nishikawa et al. (Osaka Medical and Pharmaceutical University, Takatsuki, and Hyogo College of Medicine, Japan) comprehensively...

July 5, 2021
Cancers

NASH Observatory Commented Articles

From NAFLD to NASH to HCC

Type 2 diabetes contributes to biological processes driving the severity of NAFLD, the primary cause for development of chronic liver diseases. Diagnosis, prevention, and treatment of the development and progression of NAFLD and NASH are important issues. In this review, H. Kim et al...

June 30, 2021

Commented Articles NASH Observatory

NASH-NAFLD: clinical impact of sexual dimorphism

NAFLD/NASH is a sex dimorphic disease, with a general higher prevalence in men. Women are at reduced risk of NAFLD compared to men in fertile age. Sexual category, sex hormones and gender habits interact with numerous NAFLD factors including cytokines, stress, and environmental factors and alter the risk profiles and phenotypes of NAFLD...

June 28, 2021

NASH Observatory Commented Articles Diagnosis Articles

Assessment of imaging modalities against liver biopsy

Multiparametric MRI is a promising technique to assess hepatic steatosis, inflammation, and fibrosis, potentially enabling non-invasive identification of individuals with active and advanced stages of NAFLD. The aim of the current proof-of-principle study by M. A. Troelstra et al. (Amsterdam University Medical Centres, The ...

June 24, 2021

NASH Observatory Commented Articles

Rising awareness on NAFLD progression by influencing threat perceptions

It is estimated that around 70% of Type 2 Diabetes Mellitus patients (T2DM) have NAFLD. Awareness and education are major shortcomings of the public health response to the increasing threat of NAFLD. Characterising the specific NAFLD-related information needs of particular high-risk metabolic communities might aid in the development of...

June 21, 2021

NASH Observatory Commented Articles Comorbidities Articles

Awareness of suffering of advanced liver disease in patients with T2D is remarkably low

The aim of the present population-based cross-sectional study is to estimate the awareness of liver disease among patients with T2D and whether it differs according to the degree of liver fibrosis estimated by transient elastography. The authors included all patients with T2D that participated in the 2017-2018 cycle of the NHAHES Survey and underwent...

June 16, 2021

NASH Observatory Commented Articles Epidemiology Articles

NAFLD burden in Australia, 2019-2030

The burden of NAFLD/NASH manifests in increasing levels of advanced liver disease and primary liver cancer in Australia. L. A. Adams et al. (The University of Western Australia, Perth, Australia) used a Markov model to forecast NAFLD burden in Australia through 2030. Prevalent NAFLD cases were projected to increase 25% from the current...

June 14, 2021